Paris Descartes University's gene therapy developer has raised $42.1m altogether following a series B featuring existing investors including Inserm Transfert Initiative.

Eyevensys, a France-based eye disease therapy developer leveraging Paris Descartes University research, closed a $30m series B round yesterday backed by Inserm Transfert Initiative, the tech transfer arm of research institute Inserm.
Pharmaceutical firm Boehringer Ingelheim led the round through its Venture Fund (BIVF), while Bpifrance, Pontifax Venture Capital, CapDecisif, Global Health Sciences (GHS) Fund and Pureos Bioventures also participated.
Founded in 2008, Eyevensys is developing gene therapies for retinal and ophthalmological diseases. Its approach allows for injecting…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?